These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16132345)

  • 21. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
    Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.
    Tagen M; Zhuang Y; Zhang F; Harstead KE; Shen J; Schaiquevich P; Fraga CH; Panetta JC; Waters CM; Stewart CF
    Drug Metab Lett; 2010 Dec; 4(4):195-201. PubMed ID: 20583968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
    Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
    Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    Lee HJ; Choi CH
    BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state.
    Sauna ZE; Nandigama K; Ambudkar SV
    J Biol Chem; 2004 Nov; 279(47):48855-64. PubMed ID: 15364914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
    Sawyer TE; Bonner JA
    Br J Cancer Suppl; 1996 Jul; 27():S109-13. PubMed ID: 8763860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
    Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
    Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
    Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
    Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan (CPT-11): a brief overview.
    Rivory LP
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
    Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
    Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
    Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
    Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
    Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
    Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
    Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.